Because of the anti-inflammatory and anti-tumor properties of HDAC inhibition, deacetylase inhibitors have potential for treatment of IBD and IBD associated colorectal cancer, further reviewed in Refs. This evidence concerns the gene HDAC9 and neoplasm.